Director Robert F. Williamson III filed a Form 4 with the SEC on November 19, 2026, disclosing a purchase of 15,000 shares of common stock in Perspective Therapeutics, Inc. (NYSE:CATX) on November 18, 2026.

Key Highlights

  • Reporting person: Robert F. Williamson III, listed as a Director of Perspective Therapeutics, Inc.
  • Transaction: Purchase (Code P) of 15,000 shares of common stock on November 18, 2026.
  • Price per share: $0.8, as stated in the filing.
  • Post-transaction indirect holdings: 68,473 shares beneficially owned indirectly through the RFW3 Revocable Trust following the reported transaction.
  • Direct holdings reported: 115,271 shares held directly (disposed designation D in Table I, no transaction code listed for that row).
  • Filing signed: By Chris Nenno as Attorney-in-Fact for Robert F. Williamson III on November 19, 2026.

Williamson's November 2026 Purchase and Beneficial Ownership at Perspective Therapeutics

According to the Form 4 filed on November 19, 2026, Director Robert F. Williamson III acquired 15,000 shares of Perspective Therapeutics, Inc. common stock on November 18, 2026, at a price of $0.8 per share. The transaction was coded as a purchase (Code P) under Table I - Non-Derivative Securities. The filing does not indicate that the transaction was made pursuant to a Rule 10b5-1(c) plan, as that checkbox was not checked.

Following the reported transaction, the filing discloses that Williamson indirectly beneficially owns 68,473 shares through the RFW3 Revocable Trust. A separate row in Table I lists 115,271 shares with a direct (D) ownership form and a disposition designation, though no transaction date or transaction code is associated with that row in the filing. No derivative securities transactions were reported in Table II.

The filing was submitted by Chris Nenno as Attorney-in-Fact on behalf of Williamson. Perspective Therapeutics, Inc. trades on the NYSE under the ticker symbol CATX, as identified in the issuer field of the filing.

What Was Disclosed

The filing reports a single open-market purchase of 15,000 shares of Perspective Therapeutics common stock by Director Robert F. Williamson III at $0.8 per share on November 18, 2026, with post-transaction indirect beneficial ownership of 68,473 shares through the RFW3 Revocable Trust.